Ambrx Biopharma, Inc. - Common Stock (NY:AMAM)

N/A UNCHANGED

Last Price Updated: 7:00 PM EDT, Mar 16, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ambrx Biopharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment

December 09, 2022

From Ambrx Biopharma Inc.

Via Business Wire

Why Express Shares Are Trading Higher By 39%? Here Are 50 Stocks Moving In Thursday's Mid-Day Session ↗

December 08, 2022

Gainers My Size, Inc. (NASDAQ: MYSZ) shares jumped 88% to $0.2839. My Size announced a 1-for-25 reverse stock split.

Via Benzinga

Ambrx Biopharma Stops Working On Breast Cancer Candidate, Cites Competition As The Reason ↗

October 19, 2022

Via Benzinga

Ambrx Announces Abrupt Leadership Change, Discuses Pipeline Review ↗

August 17, 2022

Via Benzinga

Ambrx Biopharma's ARX788 Selected For Phase 2 Adaptive Breast Cancer Trial ↗

April 26, 2022

Via Benzinga

Why Summit Therapeutics Shares Are Trading Higher By Over 82%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session ↗

December 06, 2022

Gainers Summit Therapeutics Inc. (NASDAQ: SMMT) shares surged 82.2% to $1.4299 after the company announced a definitive agreement of its partnership with Akeso to in-license its breakthrough bispecific...

Via Benzinga

Why MEI Pharma Shares Are Trading Lower By Around 35%; Here Are 20 Stocks Moving Premarket ↗

December 06, 2022

Gainers Starry Group Holdings, Inc. (NYSE: STRY) shares rose 43.5% to $0.2011 in pre-market trading after dipping more than 20% on Monday.

Via Benzinga

Earnings Scheduled For April 26, 2022 ↗

April 26, 2022

Companies Reporting Before The Bell • First American Financial (NYSE:FAF) is estimated to report quarterly loss at $0.09 per share on revenue of $46.41 million.

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

December 05, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

November 18, 2022

On Friday, 64 companies achieved new lows for the year.

Via Benzinga

Week In Review: Insilico Signs Six-Drug Discovery Deal With Sanofi Worth Up To $1.2 Billion ↗

November 12, 2022

Insilico Medicine signed a six-drug research collaboration with Sanofi that could be worth up to $1.2 billion. Insilico will receive up to $21.5 million in upfront and target nomination fees for each...

Via Talk Markets

Ambrx Announces NovoCodex’s Dosing of First Patient with ARX305, Ambrx’s Investigational Antibody Drug Conjugate Targeting CD70

November 09, 2022

From Ambrx

Via Business Wire

Ambrx Biopharma Inc. Appoints Daniel O’Connor as Chief Executive Officer

November 01, 2022

From Ambrx

Via Business Wire

Stocks That Hit 52-Week Lows On Monday ↗

September 12, 2022

During Monday's session, 38 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

October 25, 2022

On Tuesday, 120 companies set new 52-week lows.

Via Benzinga

Why Minerva Neurosciences Shares Dipped By Around 70%; Here Are 90 Biggest Movers From Yesterday ↗

October 18, 2022

Gainers Acorda Therapeutics, Inc. (NASDAQ: ACOR) surged 163.8% to close at $0.8970 on Monday after the company announced a $16.5 million award and royalty/supply relief in the AMPYRA arbitration case.

Via Benzinga

Why Bank of America Shares Are Trading Higher? Here Are 66 Stocks Moving In Monday's Mid-Day Session ↗

October 17, 2022

Gainers FedNat Holding Company (NASDAQ: FNHC) shares rose 78.9% to $0.93 after jumping 48% on Friday.

Via Benzinga

Ambrx Biopharma Inc. Reports 1H 2022 Financial Results and Provides Corporate Update

August 29, 2022

From Ambrx, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Thursday ↗

August 18, 2022

During Thursday's trading, 62 companies set new 52-week lows.

Via Benzinga

Ambrx Biopharma Appoints Kate Hermans as Interim CEO, Replacing Feng Tian

August 16, 2022

From Ambrx, Inc.

Via Business Wire

Ambrx Biopharma Appoints Edward Hu and Kate Hermans to its Board of Directors

July 05, 2022

From Ambrx, Inc.

Via Business Wire

Ambrx Biopharma Inc. to Present at the H.C. Wainwright Preclinical Cancer Drug Discover Conference

June 28, 2022

From Ambrx, Inc.

Via Business Wire

Ambrx Biopharma Inc. Appoints Janet Loesberg to Board of Directors

June 06, 2022

From Ambrx, Inc.

Via Business Wire

Ambrx Biopharma Inc. to Participate in Upcoming Investor Conferences

May 27, 2022

From Ambrx, Inc.

Via Business Wire

Ambrx Biopharma Inc. Appoints Janice Lu, M.D., Ph.D., as Chief Medical Officer

May 17, 2022

From Ambrx, Inc.

Via Business Wire

Ambrx Biopharma Inc. to Present at Upcoming Investor Conferences

May 06, 2022

From Ambrx, Inc.

Via Business Wire

Ambrx Biopharma Inc. Announces Filing of Annual Report on Form 20-F

May 02, 2022

From Ambrx Biopharma Inc.

Via Business Wire

Ambrx Biopharma Inc. Reports Full Year 2021 Financial Results; Provides Corporate Update

April 26, 2022

From Ambrx, Inc.

Via Business Wire

The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy ↗

April 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Ambrx Biopharma Inc. and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of ARX788 in the I-SPY 2.2 Phase 2 Adaptive Clinical Trial for Breast Cancer

April 25, 2022

From Ambrx, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.